CVKD
Income statement / Annual
Last year (2023), Cadrenal Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Cadrenal Therapeutics, Inc. Common Stock's net income was -$8.36 M.
See Cadrenal Therapeutics, Inc. Common Stock’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00
|
$0.00
|
| Cost of Revenue |
$1,980.00 |
$1,266.00 |
| Gross Profit |
-$1,980.00 |
-$1,266.00 |
| Gross Profit Ratio |
0 |
0 |
| Research and Development
Expenses |
$4.08 M
|
$392,859.00
|
| General & Administrative
Expenses |
$3.55 M
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$3.55 M
|
$2.31 M
|
| Other Expenses |
$1,980.00 |
$0.00 |
| Operating Expenses |
$7.63 M |
$2.70 M |
| Cost And Expenses |
$7.63 M |
$2.70 M |
| Interest Income |
$249,092.00 |
$0.00 |
| Interest Expense |
$17,101.00 |
$107,105.00 |
| Depreciation &
Amortization |
$1,980.00
|
$1,266.00
|
| EBITDA |
-$7.63 M
|
-$2.70 M
|
| EBITDA Ratio |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$724,246.00
|
-$4.01 M
|
| Income Before Tax |
-$8.36 M |
-$6.71 M |
| Income Before Tax Ratio
|
0
|
0
|
| Income Tax Expense |
-$165,915.00 |
$4.00 |
| Net Income |
-$8.36 M |
-$6.71 M |
| Net Income Ratio |
0 |
0 |
| EPS |
-9.63 |
-8.66 |
| EPS Diluted |
-9.63 |
-8.66 |
| Weighted Average Shares
Out |
$868,180.00
|
$775,638.00
|
| Weighted Average Shares
Out Diluted |
$868,180.00
|
$775,638.00
|
| Link |
|
|
